Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
499.17
+38.30 (8.31%)
At close: Mar 10, 2026, 4:00 PM EDT
500.25
+1.08 (0.22%)
After-hours: Mar 10, 2026, 7:52 PM EDT
Vertex Pharmaceuticals Revenue
In the year 2025, Vertex Pharmaceuticals had annual revenue of $12.00B with 8.90% growth. Vertex Pharmaceuticals had revenue of $3.19B in the quarter ending December 31, 2025, with 9.55% growth.
Revenue (ttm)
$12.00B
Revenue Growth
+8.90%
P/S Ratio
10.57
Revenue / Employee
$1,875,203
Employees
6,400
Market Cap
126.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.00B | 981.20M | 8.90% |
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
| Dec 31, 2018 | 3.05B | 558.95M | 22.46% |
| Dec 31, 2017 | 2.49B | 786.48M | 46.20% |
| Dec 31, 2016 | 1.70B | 669.84M | 64.89% |
| Dec 31, 2015 | 1.03B | 451.92M | 77.86% |
| Dec 31, 2014 | 580.42M | -631.56M | -52.11% |
| Dec 31, 2013 | 1.21B | -315.07M | -20.63% |
| Dec 31, 2012 | 1.53B | 116.42M | 8.25% |
| Dec 31, 2011 | 1.41B | 1.27B | 883.91% |
| Dec 31, 2010 | 143.37M | 41.48M | 40.71% |
| Dec 31, 2009 | 101.89M | -73.62M | -41.94% |
| Dec 31, 2008 | 175.50M | -23.51M | -11.81% |
| Dec 31, 2007 | 199.01M | -17.34M | -8.02% |
| Dec 31, 2006 | 216.36M | 55.47M | 34.47% |
| Dec 31, 2005 | 160.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.34B |
| BeOne Medicines AG | 5.34B |
| Incyte | 5.14B |
| argenx SE | 4.25B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
VRTX News
- 13 hours ago - This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results - Investopedia
- 13 hours ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 16 hours ago - Vertex passes key test In quest to treat kidney diseases - CNBC
- 1 day ago - Vertex's kidney disease drug meets main goal in late-stage trial - Reuters
- 1 day ago - Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - Business Wire
- 5 days ago - Vertex to Participate in Upcoming March Investor Conferences - Business Wire
- 5 days ago - Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures - Business Wire
- 7 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha